HER2 Expression and Chemotherapy in Breast Cancer
Author Information
Author(s): Del Mastro L, Bruzzi P, Nicolò G, Cavazzini G, Contu A, D'Amico M, Lavarello A, Testore F, Castagneto B, Aitini E, Perdelli L, Bighin C, Rosso R, Venturini Marco
Primary Institution: National Cancer Research Institute, Genoa, Italy
Hypothesis
Does HER2 overexpression predict the efficacy of dose-dense anthracycline-containing adjuvant chemotherapy in breast cancer patients?
Conclusion
HER2 overexpression is associated with worse event-free and overall survival in patients treated with standard chemotherapy, but the negative impact may be mitigated with dose-dense chemotherapy.
Supporting Evidence
- HER2 overexpression was associated with a poor prognosis in breast cancer patients.
- Event-free survival was significantly worse in HER2 positive patients treated with standard chemotherapy.
- Dose-dense chemotherapy may mitigate the negative prognostic effect of HER2 overexpression.
Takeaway
This study looked at how a specific protein called HER2 affects breast cancer treatment. It found that patients with high levels of HER2 might do worse with standard treatment but could benefit more from a faster treatment schedule.
Methodology
The study evaluated HER2 status in a subgroup of patients from a phase III trial comparing standard vs dose-dense chemotherapy, analyzing event-free and overall survival.
Potential Biases
Potential selection bias due to the retrospective nature of the study.
Limitations
The study is retrospective, has limited power due to a small number of HER2-positive patients, and lacks FISH testing for HER2 status.
Participant Demographics
Patients were women aged ≤70 years with histologically confirmed breast cancer, with various tumor characteristics.
Statistical Information
P-Value
0.001
Confidence Interval
95% CI 1.34–4.57
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website